SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 210 filers reported holding SANGAMO THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is 1.25 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $266,369 | -53.5% | 443,948 | +0.7% | 0.00% | 0.0% |
Q2 2023 | $573,216 | +1.8% | 440,935 | +37.8% | 0.00% | 0.0% |
Q1 2023 | $563,263 | +26.7% | 320,036 | +126.1% | 0.00% | 0.0% |
Q4 2022 | $444,401 | -72.9% | 141,529 | -57.6% | 0.00% | -80.0% |
Q3 2022 | $1,637,000 | -45.8% | 333,785 | -54.2% | 0.01% | -37.5% |
Q2 2022 | $3,021,000 | -52.0% | 729,350 | -32.7% | 0.01% | -42.9% |
Q1 2022 | $6,299,000 | +73.4% | 1,084,204 | +123.9% | 0.01% | +100.0% |
Q4 2021 | $3,632,000 | +4944.4% | 484,272 | +5965.5% | 0.01% | – |
Q3 2021 | $72,000 | +278.9% | 7,984 | +475.6% | 0.00% | – |
Q2 2018 | $19,000 | -99.8% | 1,387 | -99.7% | 0.00% | -100.0% |
Q1 2018 | $8,110,000 | +69.1% | 426,822 | +46.0% | 0.02% | +71.4% |
Q4 2017 | $4,796,000 | +80.8% | 292,433 | +65.4% | 0.01% | +75.0% |
Q3 2017 | $2,652,000 | +103.4% | 176,794 | +19.3% | 0.01% | +100.0% |
Q2 2017 | $1,304,000 | +685.5% | 148,211 | +716.0% | 0.00% | +300.0% |
Q4 2015 | $166,000 | – | 18,162 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Golden State Equity Partners | 154,360 | $897,000 | 0.45% |
Rhenman & Partners Asset Management AB | 761,429 | $4,424,000 | 0.44% |
Lombard Odier Asset Management (Switzerland) SA | 860,702 | $5,001,000 | 0.39% |
WASATCH ADVISORS LP | 10,576,997 | $61,452,000 | 0.30% |
Rokos Capital Management LLP | 977,663 | $5,861,000 | 0.27% |
KLK CAPITAL MANAGEMENT LLC | 44,323 | $258,000 | 0.26% |
Long Focus Capital Management, LLC | 340,000 | $1,975,000 | 0.25% |
Vanguard Capital Wealth Advisors | 33,380 | $193,000 | 0.14% |
Fort Sheridan Advisors LLC | 73,978 | $430,000 | 0.13% |
Delphia (USA) Inc. | 20,983 | $122,000 | 0.09% |